Stryker cautious after BofA and Barclays trim targets, shares stay firm in S&P 500
24.06.2026 - 11:37:35 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-24, 11:35.
Stryker Corp. (US8636671013) sits against a cooler analyst backdrop today. Major houses including Bank of America and Barclays have recently cut their price targets following what they described as mixed first quarter 2026 figures, while the stock holds its place in the S&P 500 index.
What recent analyst notes show
Bank of America has lowered its target on Stryker, citing early signs of a broader medtech slowdown and pointing to valuation that already prices in robust growth, according to a June 22 note referenced by finanzen100. In parallel, Barclays has also trimmed its price target and called the company’s first quarter 2026 results mixed, highlighting the earnings miss versus consensus despite solid underlying procedure volumes.
MarketBeat data shows that for the first quarter of 2026, reported earnings per share came in at 2.60 dollars, below the consensus estimate of 2.98 dollars, a shortfall of 0.38 dollars per share. Even with that miss, Stryker reaffirmed a relatively tight full-year 2026 earnings guidance range between 14.90 and 15.10 dollars per share, roughly in line with the average analyst expectation of 14.95 dollars. This combination of an earnings miss but maintained guidance has helped frame the cautious tone in recent research reports from large banks.
Consensus picture on Stryker shares
Despite the target cuts, Stryker still carries an overall constructive analyst consensus, with multiple brokers maintaining Buy or Overweight ratings according to MarketBeat’s compiled coverage of the NYSE-listed shares. The stock most recently closed at 310.43 dollars on June 23, 2026 on the NYSE, up 1.88 percent for that session, with after-hours indications around 307 to 310 dollars showing only muted volatility.
Stockscan collates analyst forecasts pointing to an average price target of about 438.87 dollars, implying an upside of roughly 42 percent from the current price near 310 dollars, albeit with a wide range of expectations. The highest reported target in that dataset is around 450 dollars, while the lowest sits just above 427 dollars, illustrating that even as individual houses like Bank of America and Barclays turn more cautious, the broader sell-side community still models meaningful growth in earnings and free cash flow over the medium term.
More news and data on the Stryker shares
Background articles, consensus updates and price data on Stryker can be found in the dedicated topic section and on the company’s investor relations pages.
The products behind Stryker’s revenues
Stryker generates most of its sales from orthopaedic implants, surgical equipment and neurotechnology solutions, with a portfolio that includes joint replacement systems, powered instruments and trauma fixation platforms. Recent announcements highlight an expansion of the trauma product range in Europe via the Pangea plating system platform and the launch of the TPX HD power tool for demanding orthopaedic procedures, underlining the company’s focus on complex surgical use cases.
Where the stock trades today
The Stryker shares (US8636671013) last closed on the NYSE at 310.43 dollars on 2026-06-23 at 15:58 Eastern time, with extended trading indications around 307 to 310 dollars in early June 24 data. That price level values the medical equipment group comfortably within the S&P 500, reflecting both the medtech sector’s structural growth profile and investors’ current willingness to look through short-term earnings volatility.
Key data on the Stryker shares
- Company: Stryker Corporation
- ISIN: US8636671013
- WKN: 864952
- Ticker: SYK
- Trading venue: NYSE
- Price (as of 2026-06-23, 15:58): 310.43 USD
- Market cap: approximately 118 billion USD (as of 2026-06-23, based on the latest NYSE price and share count reported in market data).
- Sector / industry: Health Care / Medical Equipment
- Index membership: S&P 500
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. All data and statements are based on sources believed to be reliable at the time of publication, but completeness and accuracy cannot be guaranteed. Investors should conduct their own research or consult a qualified advisor before making investment decisions.
